SUMMARY Cyclosporin toxicity may produce a wide range of neurological disorders. We report three patients whose neurological problems developed while taking cyclosporin following cardiac transplantation, but resolved rapidly when the drug was discontinued. In two cases, MRI revealed abnormalities which disappeared with clinical recovery. Blood cyclosporin concentrations were not markedly increased, and it is possible that the neurotoxic effects of cyclosporin are mediated by metabolites, through an effect on the blood-brain barrier. EEG, CT brain scan and CSF examinations were unremarkable. Whole blood cyclosporin level was 438 ng/ml (therapeutic range 100-400 ng/ml). He improved somewhat over the next few days but remained slightly confused and was eventually readmitted on 11 September 1986 with an acute recurrence of his original symptoms, together with a severe postural tremor and a mild left hemiparesis. This progressed over the next 24 hours to generalised myoclonus and ultimately status epilepticus and coma. CT, serological and CSF examinations were again unremarkable and no pathogens could be identified. Although the blood cyclosporin level was acceptable at 462 ng/ml, the drug was withdrawn and within 12 hours he made a dramatic recovery, with eventual resolution of his confusional state and myoclonus. Two MRI studies were performed. The first, 2 days after the initial admission, showed a focal area of increased signal density, without mass effect, in the medial surface of the temporal lobe on the right, and a similar abnormal signal in the right cerebellar hemisphere (fig la and b) . One week after stopping the cyclosporin these abnormal signals had diminished significantly. Six months later, he remains well despite being on a small maintenance dose of cyclosporin because of recurrent rejection.
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A number of reports EEG, CT brain scan and CSF examinations were unremarkable. Whole blood cyclosporin level was 438 ng/ml (therapeutic range 100-400 ng/ml). He improved somewhat over the next few days but remained slightly confused and was eventually readmitted on 11 September 1986 with an acute recurrence of his original symptoms, together with a severe postural tremor and a mild left hemiparesis. This progressed over the next 24 hours to generalised myoclonus and ultimately status epilepticus and coma. CT, serological and CSF examinations were again unremarkable and no pathogens could be identified. Although the blood cyclosporin level was acceptable at 462 ng/ml, the drug was withdrawn and within 12 hours he made a dramatic recovery, with eventual resolution of his confusional state and myoclonus. Two MRI studies were performed. The first, 2 days after the initial admission, showed a focal area of increased signal density, without mass effect, in the medial surface of the temporal lobe on the right, and a similar abnormal signal in the right cerebellar hemisphere (fig la and b Mg"+ remained low (0-66 mM) after recovery. The whole blood cyclosporin level in February had been 56 ng/ml, but was found to be in the toxic range at 669 ng/ml on admission, although the dose of drug taken had not been changed over this period. MRI two days after admission showed an unusual bright density in the left corona radiata and some Lane, Roche, Leung, Greco, Lange less prominent abnormal signals in the right occipital and left frontal cortex (fig 2a, b and c) . A second study one month after recovery showed complete resolution of these lesions.
Discussion
Seizures associated with cyclosporin treatment were first described in bone marrow transplant recipients, and subsequently in renal and liver transplant patients. Most cases of cyclosporin neurotoxicity have occurred with high doses and drug levels above the accepted therapeutic range, but there is no general correlation between blood levels and toxic effects in other systems in cardiac transplant patients.8 Levels in two of our patients were within or only slightly above the accepted therapeutic range, and it is possible that the neurotoxic effects are in fact mediated by metabolites of cyclosporin, which can be detected in blood by high performance liquid chromatography.'0 A close association between neurotoxic effects and hypomagnesaemia, possibly caused by the nephrotoxic action of the drug, was noted in one series of bone marrow transplant recipients9 and could have been an aggravating factor in our third patient, although our patient recovered despite persistently low serum Mg"+ levels.
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